This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garcia, A. Articles by Arbiser, J. L. Search for Related Content PubMed PubMed Citation Articles by Garcia, A. Articles by Arbiser, J. L.

Honokiol Suppresses Survival Signals Mediated by Ras-Dependent Phospholipase D Activity in Human Cancer Cells

Authors' Affiliations: ¹ Department of Biological Sciences, Hunter College of The City University of New York and ² Department of Biochemistry, New York University School of Medicine, New York, New York; ³ Department of Pharmacology, Institute for Chemical Biology, and Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; and ⁴ Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia

Requests for reprints: David A. Foster, Department of Biological Sciences, Hunter College of the City University of New York, 695 Park Avenue, New York, NY 10021. Phone: 212-772-4075; Fax: 212-772-5227; E-mail: foster{at}genectr.hunter.cuny.edu.

Purpose: Elevated phospholipase D (PLD) activity provides a survival signal in several human cancer cell lines and suppresses apoptosis when cells are subjected to the stress of serum withdrawal. Thus, targeting PLD survival signals has potential to suppress survival in cancer cells that depend on PLD for survival. Honokiol is a compound that suppresses tumor growth in mouse models. The purpose of this study was to investigate the effect of honokiol on PLD survival signals and the Ras dependence of these signals.

Experimental Design: The effect of honokiol upon PLD activity was examined in human cancer cell lines where PLD activity provides a survival signal. The dependence of PLD survival signals on Ras was investigated, as was the effect of honokiol on Ras activation.

Results: We report here that honokiol suppresses PLD activity in human cancer cells where PLD has been shown to suppress apoptosis. PLD activity is commonly elevated in response to the stress of serum withdrawal, and, importantly, the stress-induced increase in PLD activity is selectively suppressed by honokiol. The stress-induced increase in PLD activity was accompanied by increased Ras activation, and the stress-induced increase in PLD activity in MDA-MB-231 breast cancer cells was dependent on a Ras. The PLD activity was also dependent on the GTPases RalA and ADP ribosylation factor. Importantly, honokiol suppressed Ras activation.

Conclusion: The data provided here indicate that honokiol may be a valuable therapeutic reagent for targeting a large number of human cancers that depend on Ras and PLD for their survival.

This article has been cited by other articles:

				A. Toschi, E. Lee, L. Xu, A. Garcia, N. Gadir, and D. A. Foster Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin Mol. Cell. Biol., March 15, 2009; 29(6): 1411 - 1420. [Abstract] [Full Text] [PDF]

				W. Su, O. Yeku, S. Olepu, A. Genna, J.-S. Park, H. Ren, G. Du, M. H. Gelb, A. J. Morris, and M. A. Frohman 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a Phospholipase D Pharmacological Inhibitor That Alters Cell Spreading and Inhibits Chemotaxis Mol. Pharmacol., March 1, 2009; 75(3): 437 - 446. [Abstract] [Full Text] [PDF]